Cancer Research Aziza Shad  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 44, 1409-1414, April 1, 1984]
© 1984 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, C. M.
Right arrow Articles by Zava, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, C. M.
Right arrow Articles by Zava, D. T.

Estrogen Receptor-mediated and Cytotoxic Effects of the Antiestrogens Tamoxifen and 4-Hydroxytamoxifen

Carol M. Taylor1, Beatrix Blanchard and David T. Zava

Ludwig Institute for Cancer Research, Bern Branch Inselspital, 3010 Bern, Switzerland

The triphenylethylene antiestrogen tamoxifen (TAM) is believed to exert its antitumor effect via the estrogen receptor (ER). To test this hypothesis and to differentiate between ER-mediated and general cytotoxic effects of TAM, the growth-inhibitory effects of TAM and its in vivo metabolite 4-hydroxytamoxifen (OH-TAM) have been studied in five continuous human cancer cell lines, MCF7 and T47D (mammary carcinoma, ER positive), BT20 and MDA-MB-231 (mammary carcinoma, ER negative), and ME8 (melanoma, ER negative). All five cell lines are completely killed by concentrations of TAM and OH-TAM above 10-6M, regardless of ER status. TAM and OH-TAM have little effect on the ER-negative lines at concentrations below 10-6 M, whereas the ER-positive lines are highly sensitive to TAM at 10-7 M and to OH-TAM at 10-9 M. Inhibition of growth parallels the relative affinity of these drugs for the ER. We conclude that, above 10-6 M, the growth-inhibitory effects of TAM and OH-TAM in tissue culture are the results of a mechanism other than that via the ER system and that only at lower concentrations are the true ER-mediated effects seen. Plasma concentrations of TAM and OH-TAM in breast cancer patients treated with TAM are in the same range as the concentrations in vivo at which growth inhibition is seen, leading to the conclusion that both compounds contribute to the overall effect of TAM in vivo.

1 To whom requests for reprints should be addressed.

Received 9/19/83. Accepted 12/27/83.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
M. J. Chisamore, H. A. Wilkinson, O. Flores, and J. D. Chen
Estrogen-related receptor-{alpha} antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts
Mol. Cancer Ther., March 1, 2009; 8(3): 672 - 681.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
P. C.K. Leung and J.-H. Choi
Endocrine signaling in ovarian surface epithelium and cancer
Hum. Reprod. Update, March 1, 2007; 13(2): 143 - 162.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. R. Kisanga, J. Gjerde, A. Guerrieri-Gonzaga, F. Pigatto, A. Pesci-Feltri, C. Robertson, D. Serrano, G. Pelosi, A. Decensi, and E. A. Lien
Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial
Clin. Cancer Res., April 1, 2004; 10(7): 2336 - 2343.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Mabuchi, M. Ohmichi, A. Kimura, Y. Ikebuchi, K. Hisamoto, E. Arimoto-Ishida, Y. Nishio, K. Takahashi, K. Tasaka, and Y. Murata
Tamoxifen Inhibits Cell Proliferation via Mitogen-Activated Protein Kinase Cascades in Human Ovarian Cancer Cell Lines in a Manner Not Dependent on the Expression of Estrogen Receptor or the Sensitivity to Cisplatin
Endocrinology, March 1, 2004; 145(3): 1302 - 1313.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. A. Mobley and R. W. Brueggemeier
Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer
Carcinogenesis, January 1, 2004; 25(1): 3 - 9.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
Vijayalaxmi, C. R. Thomas Jr, R. J. Reiter, and T. S. Herman
Melatonin: From Basic Research to Cancer Treatment Clinics
J. Clin. Oncol., May 15, 2002; 20(10): 2575 - 2601.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Mandlekar, R. Yu, T.-H. Tan, and A.-N. T. Kong
Activation of Caspase-3 and c-Jun NH2-terminal Kinase-1 Signaling Pathways in Tamoxifen-induced Apoptosis of Human Breast Cancer Cells
Cancer Res., November 1, 2000; 60(21): 5995 - 6000.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
S. S. Legha
Tamoxifen in the Treatment of Breast Cancer
Ann Intern Med, August 1, 1988; 109(3): 219 - 228.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1984 by the American Association for Cancer Research.